SCHEMBL2631946

SCHEMBL2631946

CCCCOCC1OC(OC)[C@@H](OCCCC)[C@H]1OCCCC

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SSTR1 P30872 4/20 0.52
SSTR2 P30874 4/20 0.52
SSTR4 P31391 4/20 0.52
SSTR3 P32745 4/20 0.52
SSTR5 P35346 4/20 0.52
TNF P01375 2/20 0.46
GJB2 P29033 4/20 0.44
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
FGF1 P05230 3/20 0.33
FGF2 P09038 3/20 0.33
VEGFA P15692 3/20 0.33
HPSE Q9Y251 3/20 0.33
PTPN2 P17706 1/20 0.33
PTPN1 P18031 1/20 0.33
ADRB2 P07550 1/20 0.33
TACR1 P25103 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15505950 1.00 SSTR1 (0.52) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL280500 1.00 SSTR1 (0.52) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL13222916 1.00 SSTR1 (0.52) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL15871861 1.00 SSTR1 (0.52) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL13081507 1.00 SSTR1 (0.52) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL14605404 1.00 SSTR1 (0.52) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL15003969 1.00 SSTR1 (0.52) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL13605427 0.98 SSTR1 (0.54) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL19356278 0.98 SSTR1 (0.54) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL15886871 0.98 SSTR1 (0.54) SSTR1SSTR2SSTR4SSTR3SSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9764036-B2 Lipids and compositions for the delivery of therapeutics ARBUTUS BIOPHARMA CORPORATION (CA) 2017-09-19 US disclosed
US-20160213785-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2016-07-28 US disclosed
US-9220683-B2 Lipids and compositions for the delivery of therapeutics TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2015-12-29 US disclosed
US-20120095075-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-04-19 US disclosed
US-20120027796-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160213785-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS CETP, LCAT, NPC1L1 SSTR1 3309/4885SSTR2 2737/4885SSTR4 2827/4885
US-20120095075-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS CETP, LCAT, NPC1L1 SSTR1 3448/4885SSTR2 2888/4885SSTR4 3010/4885
US-20120027796-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS CETP, ABCB4, LCAT SSTR1 3077/4885SSTR2 2456/4885SSTR4 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.